Literature DB >> 2802520

Using the LMS method to measure skewness in the NCHS and Dutch National height standards.

T J Cole1.   

Abstract

The American National Center for Health Statistics (NCHS) and Dutch national height growth standards, unlike previous standards, allowed for skewness when fitting the centile curves. The LMS method (Cole 1988) is a way of summarizing growth standards which monitors the changing skewness of the distribution during childhood. It does so by calculating the Box-Cox power needed to transform the data to normality at each age, and displaying the results as a smooth curve of power plotted against age. Applying the LMS method to the NCHS and Dutch standards highlights the nature of the changing skewness of height during childhood, and particularly during puberty. Taken in conjunction with curves for the mean and coefficient of variation of height plotted against age, the power curve allows the original centiles to be reconstructed to high accuracy. This provides further evidence that the LMS method is a powerful and compact technique for deriving and presenting growth standards.

Mesh:

Year:  1989        PMID: 2802520     DOI: 10.1080/03014468900000532

Source DB:  PubMed          Journal:  Ann Hum Biol        ISSN: 0301-4460            Impact factor:   1.533


  15 in total

1.  Growth Charts for Individuals with Mucopolysaccharidosis VI (Maroteaux-Lamy Syndrome).

Authors:  Adrian Quartel; Christian J Hendriksz; Rossella Parini; Sue Graham; Ping Lin; Paul Harmatz
Journal:  JIMD Rep       Date:  2014-12-18

2.  Evaluating 12 Years of Implementing a Multidisciplinary Specialist Child and Adolescent Obesity Treatment Service: Patient-Level Outcomes.

Authors:  Cathy Wyse; Lucinda Case; Órla Walsh; Catherine Shortall; Norah Jordan; Lois McCrea; Grace O'Malley
Journal:  Front Nutr       Date:  2022-06-03

3.  Body proportions before and during growth hormone therapy in children with chronic renal failure.

Authors:  Laura C G de Graaff; Paul G H Mulder; Anita C S Hokken-Koelega
Journal:  Pediatr Nephrol       Date:  2003-05-07       Impact factor: 3.714

4.  Pregnanetriol in the Range of 1.2-2.1 mg/m(2)/day as an Index of Optimal Control in CYP21A2 Deficiency.

Authors:  Masako Izawa; Keiko Aso; Asako Higuchi; Daisuke Ariyasu; Yukihiro Hasegawa
Journal:  Clin Pediatr Endocrinol       Date:  2007-05-17

5.  Weight centile crossing in infancy: correlations between successive months show evidence of growth feedback and an infant-child growth transition.

Authors:  Tim J Cole; Atul Singhal; Mary S Fewtrell; Jonathan Ck Wells
Journal:  Am J Clin Nutr       Date:  2016-09-07       Impact factor: 7.045

6.  International estimated fetal weight standards of the INTERGROWTH-21st Project.

Authors:  J Stirnemann; J Villar; L J Salomon; E Ohuma; P Ruyan; D G Altman; F Nosten; R Craik; S Munim; L Cheikh Ismail; F C Barros; A Lambert; S Norris; M Carvalho; Y A Jaffer; J A Noble; E Bertino; M G Gravett; M Purwar; C G Victora; R Uauy; Z Bhutta; S Kennedy; A T Papageorghiou
Journal:  Ultrasound Obstet Gynecol       Date:  2017-03-05       Impact factor: 7.299

7.  Growth diagrams for grip strength in children.

Authors:  H M Ties Molenaar; Ruud W Selles; J Michiel Zuidam; Sten P Willemsen; Henk J Stam; Steven E R Hovius
Journal:  Clin Orthop Relat Res       Date:  2009-05-21       Impact factor: 4.176

8.  Body mass index reference curves for children aged 0-18 years in shaanxi, china.

Authors:  Lei Shang; Yong-Yong Xu; Xun Jiang; Ru-Lan Hou
Journal:  Int J Biomed Sci       Date:  2005-06

9.  Impact of placental weight and fetal/placental weight ratio Z score on fetal growth and the perinatal outcome.

Authors:  Yoshio Matsuda; Toshiya Itoh; Hiroaki Itoh; Masaki Ogawa; Kemal Sasaki; Naohiro Kanayama; Shigeki Matsubara
Journal:  Int J Med Sci       Date:  2018-03-08       Impact factor: 3.738

10.  Statistical methodology for constructing gestational age-related charts using cross-sectional and longitudinal data: The INTERGROWTH-21st project as a case study.

Authors:  Eric O Ohuma; Douglas G Altman
Journal:  Stat Med       Date:  2018-11-28       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.